Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study (scientific article published on 14 December 2017)

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

Q34116750

Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan

Q35196603

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib.

Q36214551

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Q36286092

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.

Q37592893

Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.

Q37646889

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Q38371667

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

Q38880070

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer

Q39253416

Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors

Q39716418

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer

Q41646881

Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib

Q46149389

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Q48020812

Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms

Q48302310

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.

Q53381227

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC.

Q53753820

RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.

Q54577756

P433

issue

P304

page(s)

107-116

P577

publication date

2017-12-14

P1433

published in

The Lancet. Respiratory medicine

Q27724908

P1476

title

Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study

P478

volume

Reverse relations

cites work (P2860)

Q64993921	Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
Q61810143	Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives
Q90290977	Circulating tumour DNA genomics in EGFR-mutant lung adenocarcinoma
Q92521831	Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185)
Q99582766	Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma
Q92281934	Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
Q60303033	Curative effectiveness and safety of osimertinib in the treatment for non-small-cell lung cancer: a meta-analysis of the experimental evidence
Q92783410	Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib
Q60914312	Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice
Q64089193	Emerging therapies for non-small cell lung cancer
Q94545830	Genetic alterations in epidermal growth factor receptor-tyrosine kinase inhibitor-naïve non-small cell lung carcinoma
Q90185351	Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer
Q58804574	Genomics of adult and pediatric solid tumors
Q90018937	Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors
Q90639806	Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
Q92942818	MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
Q60302231	Mechanisms of acquired resistance to afatinib clarified with liquid biopsy
Q55401599	Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.
Q90378344	Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
Q91310921	Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer
Q90352700	Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Q92993100	TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
Q64081181	The role of osimertinib in ()-mutant non-small cell lung cancer

P356	DOI	10.1016/S2213-2600(17)30480-0
P698	PubMed publication ID	29249325